Lorenza Rimassa· @LorenzaRimassa · X·· 2 天前评分70
正文 · 原文
Zev Wainberg presents subgroup analyses from phase 3 RASolute 302 study of #daraxonrasib in patients with previously treated metastatic #PDAC at #ESMO26 (part 2) #ESMOAmbassadors @myESMO
574 浏览 · 13 赞 · 6 转发 · 0 回复
会议摘要
LBA82按 Proffered paper 1: Gastrointestinal tumour, upper digestive 对上
Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma (mPDAC): Additional subgroup analyses from the ph3 RASolute 302 study
https://esmocongress.esmo.org来源：Lorenza Rimassa · x.com